STOCK TITAN
  1. Home
  2. News
  3. 2020-12-05

Stock Market News 2020-12-05

32 news published.

2020-12-04 2020-12-06
IMPACT
SENTIMENT
12/05/2020 09:53 PM
PCG : NYSE
Potential PSPS Update: Forecasted High Winds and Dry Conditions Mean PG&E Might Proactively Turn Off Power for Safety in Targeted Portions of 16 Counties and Two Tribal Communities Beginning Early Monday Morning
IMPACT
SENTIMENT
12/05/2020 06:00 PM
GLYC : Nasdaq
GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model
IMPACT
SENTIMENT
12/05/2020 05:00 PM
REGN : Nasdaq
Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1
clinical trial
IMPACT
SENTIMENT
12/05/2020 03:01 PM
IMGN : Nasdaq
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
clinical trial
IMPACT
SENTIMENT
12/05/2020 03:01 PM
AUTL : Nasdaq
Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting
clinical trial
IMPACT
SENTIMENT
12/05/2020 03:00 PM
LEGN : Nasdaq
Legend Biotech Announces Phase 1b/2 Study Data of Cilta-cel, an Investigational BCMA CAR-T, Showing Early, Deep, and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
clinical trial
IMPACT
SENTIMENT
12/05/2020 03:00 PM
BLUE : Nasdaq
Long-Term Data for bluebird bio’s betibeglogene autotemcel (beti-cel) Gene Therapy Show Patients Across Ages and β-thalassemia Genotypes Achieve Transfusion Independence and Remain Free from Transfusions Up to Six Years Presented at 62nd ASH Meeting
IMPACT
SENTIMENT
12/05/2020 03:00 PM
AMGN : Nasdaq
Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020
conferences clinical trial
IMPACT
SENTIMENT
12/05/2020 01:45 PM
PSTX : Nasdaq
Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting
clinical trial
IMPACT
SENTIMENT
12/05/2020 01:30 PM
IGMS : Nasdaq
IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting
clinical trial low float
IMPACT
SENTIMENT
12/05/2020 01:00 PM
RARE : Nasdaq
GeneTx and Ultragenyx Announce Presentation of Phase 1/2 Data on Investigational GTX-102 in Patients with Angelman Syndrome
clinical trial
IMPACT
SENTIMENT
12/05/2020 12:45 PM
ABBV : NYSE
AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL)
IMPACT
SENTIMENT
12/05/2020 12:31 PM
SYRS : Nasdaq
Syros Presents New Data From Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML
clinical trial low float
IMPACT
SENTIMENT
12/05/2020 12:31 PM
SYRS : Nasdaq
Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies
acquisition low float
IMPACT
SENTIMENT
12/05/2020 12:30 PM
GILD : Nasdaq
Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma Study
IMPACT
SENTIMENT
12/05/2020 12:30 PM
BMY : NYSE
Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020
IMPACT
SENTIMENT
12/05/2020 12:30 PM
LLY : NYSE
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting
clinical trial
IMPACT
SENTIMENT
12/05/2020 12:30 PM
ABBV : NYSE
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
IMPACT
SENTIMENT
12/05/2020 12:30 PM
KURA : Nasdaq
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting
clinical trial
IMPACT
SENTIMENT
12/05/2020 12:30 PM
CRSP : Nasdaq
CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine
IMPACT
SENTIMENT
12/05/2020 12:30 PM
ALLO : Nasdaq
Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting
clinical trial
IMPACT
SENTIMENT
12/05/2020 11:00 AM
BNVIF : OTC
Industry Leader, Binovi Technologies, Announces Upcoming Release of Binovi Connect App
IMPACT
SENTIMENT
12/05/2020 11:00 AM
ALVR : Nasdaq
Preclinical Data Demonstrate Anti-Viral Activity of AlloVir’s ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy
clinical trial
IMPACT
SENTIMENT
12/05/2020 10:30 AM
GMDA : Nasdaq
Gamida Cell Presents Updated, Expanded Results from Phase 1 Study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and Exposition
clinical trial
IMPACT
SENTIMENT
12/05/2020 10:30 AM
SRRA : Nasdaq
Sierra Oncology Presents Long-term Overall Survival and Sustained Efficacy Outcomes Data for Momelotinib at ASH Annual Meeting
IMPACT
SENTIMENT
12/05/2020 10:00 AM
GILD : Nasdaq
New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma
IMPACT
SENTIMENT
12/05/2020 10:00 AM
GILD : Nasdaq
New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial
IMPACT
SENTIMENT
12/05/2020 10:00 AM
EDIT : Nasdaq
Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia
clinical trial
IMPACT
SENTIMENT
12/05/2020 10:00 AM
NTLA : Nasdaq
Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting
clinical trial
IMPACT
SENTIMENT
12/05/2020 10:00 AM
FULC : Nasdaq
Fulcrum Therapeutics Presents Updated Data on Sickle Cell Disease Program at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
IMPACT
SENTIMENT
12/05/2020 07:00 AM
BEAM : Nasdaq
Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease at ASH 2020
IMPACT
SENTIMENT
12/05/2020 06:35 AM
BMY : NYSE
Bristol Myers Squibb Showcases Research Advancing Outcomes Addressing Hard-to-Treat Blood Cancers and Diseases Across Small Molecule, Biologic and Cell Therapies at ASH 2020
2020-12-04 2020-12-06